Gastrointestinal and liver immune-related adverse effects induced by immune checkpoint inhibitors: A descriptive observational study
Authors:
- Patricia Sanz-SeguraPSPatricia Sanz-Segura
- Paula García-CámaraPGPaula García-Cámara
- Eva Fernández-BonillaEFEva Fernández-Bonilla
- José Miguel Arbonés-MainarJAJosé Miguel Arbonés-Mainar
- Vanesa Bernal MonterdeVMVanesa Bernal Monterde
- 1 April 2021
- journal article
- research article
- Published by Elsevier in Gastroenterología y Hepatología (English Edition)
- Vol. 44 (4) , 261-268
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Programmed cell death protein‐1 (PD‐1)‐targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real‐world cohortAlimentary Pharmacology & Therapeutics, 2019
- Immune-Related Adverse Events Associated with Immune Checkpoint BlockadeNew England Journal of Medicine, 2018
- Immune and molecular correlates in melanoma treated with immune checkpoint blockadeCancer, 2017
- PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunityNature, 2017
- Checkpoint inhibitors in gastrointestinal cancers: Expectations and realityWorld Journal of Gastroenterology, 2017
- Immune checkpoint inhibitors: a patent review (2010-2015)Expert Opinion on Therapeutic Patents, 2016
- Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanomaJournal for ImmunoTherapy of Cancer, 2015
- Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitisProceedings of the National Academy of Sciences, 2015
- Oncology Meets Immunology: The Cancer-Immunity CycleImmunity, 2013
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trialThe Lancet Oncology, 2012